Xenetic Biosciences, Inc. (XBIO)
NASDAQ: XBIO · Real-Time Price · USD
2.290
0.00 (0.00%)
Mar 9, 2026, 1:00 PM EDT - Market open
Xenetic Biosciences Employees
Xenetic Biosciences had 2 employees as of December 31, 2024. The number of employees decreased by 2 or -50.00% compared to the previous year.
Employees
2
Change (1Y)
-2
Growth (1Y)
-50.00%
Revenue / Employee
$1,429,468
Profits / Employee
-$1,578,153
Market Cap
5.25M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Quince Therapeutics | 36 |
| GeoVax Labs | 17 |
| VivoSim Labs | 14 |
| Processa Pharmaceuticals | 10 |
| MetaVia | 9 |
| Purple Biotech | 9 |
| Revelation Biosciences | 9 |
| Cyclerion Therapeutics | 1 |
XBIO News
- 3 months ago - Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting - Accesswire
- 3 months ago - Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform - Accesswire
- 4 months ago - Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results - Accesswire
- 5 months ago - Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock - Accesswire
- 7 months ago - Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results - Accesswire
- 7 months ago - Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell Lymphoma - Accesswire
- 8 months ago - Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform - Accesswire
- 8 months ago - Xenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the First Line Treatment of Unresectable, Locally Advanced or Metastatic Pancreatic Cancer - Accesswire